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Background: The prognosis of patients with metastatic osteosarcoma remains poor. However, the chance
of survival can be improved by surgical resection of all metastases. In this study we investigate the value
of serum alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) in predicting the presence of
metastatic disease at time of diagnosis.
Methods: Sixty-one patients with histologically conﬁrmed conventional osteosarcoma of the extremity
were included in the study. Only 19.7% of cases presented without evidence of systemic spread of the
disease. Pre-treatment serum ALP and LDH were analysed in patients with and without skeletal or
pulmonary metastases.
Results: Serum LDH and ALP levels were not signiﬁcantly different in patients with or without pul-
monary metastases (p¼0.88 and p¼0.47, respectively). The serum LDH and ALP levels did however differ
signiﬁcantly in patients with or without skeletal metastases (po0.001 and p¼0.02, respectively). The
optimal breakpoint for serum LDH as a marker of skeletal metastases was 849 IU/L (AUC 0.839;
Sensitivity¼0.88; Speciﬁcity¼0.73). LDH 4454 IU/L equated to 100% sensitivity for detected bone
metastases (positive diagnostic likelihood ratio (DLR)¼1.32). With a cut-off of 76 IU/L a sensitivity of
100% was reached for serum ALP predicting the presence of skeletal metastases (positive DLR¼1.1). In a
multivariate analysis both LDH Z850 IU/L (odds ratio [OR]¼9; 95% conﬁdence interval (CI) 1.8–44.3) and
ALP Z280 IU/L (OR¼10.3; 95% CI 2.1–50.5) were predictive of skeletal metastases. LDH however lost its
signiﬁcance in a multivariate model which included pre-treatment tumour volume.
Conclusion: In cases of osteosarcoma with LDH 4850 IU/L and/or ALP 4280 IU/L it may be prudent to
consider more sensitive staging investigations for detection of skeletal metastases. Further research is
required to determine the value and the most sensitive cut-off points of serum ALP and LDH in the
prediction of skeletal metastases.
& 2015 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Osteosarcoma is the most common primary bone cancer in
children and adolescents [1]. Surveillance, Epidemiology and End
Results (SEER) programme data indicates an annual incidence of
4.4 per million population in patients younger than 25 years of ageGmbH. This is an open access art
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rgery, Greys Hospital, Private[2]. The presence of metastases, at time of presentation, has been
shown to be an independently signiﬁcant risk factor in the prog-
nosis of a patient with osteosarcoma [3]. Pakos et al. analysed the
prognostic factors in 2 680 osteosarcoma cases in an international
multicentre study and found that metastases at diagnosis in-
creased the risk of mortality by a factor of 2.89 [4]. In developed
regions approximately 15% of patients with osteosarcoma present
with metastatic disease [5]. In under-developed regions higher
rates of metastases have been found at time of diagnosis. This is
illustrated in previous studies from South Africa, where evidence
of systemic spread was found in 47–66% of patients at time of
presentation [6,7].
Implementation of contemporary treatment protocols, incorporat-
ing adjuvant chemotherapy, have resulted in an improvement in the
prognosis of patients diagnosed with osteosarcoma over the pasticle under the CC BY-NC-ND license
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20% in the 1960s to approximately 60% [8]. The prognosis, however,
remains unsatisfactory in cases with metastases, with an overall
5-year survival rate of less than 30% [8]. Owing to the fact that long-
term survival can be improved to over 40%, the European Society of
Medical Oncology (ESMO) recommends mandatory excision of all
metastatic lesions in patient diagnosed with osteosarcoma [8,9]. It is
therefore essential that all patients with metastatic disease are iden-
tiﬁed timeously. In addition, there is a need for markers which identify
patients with a poor prognosis so that more aggresive treatment op-
tions can be implemented in an effort to improve their prognosis [9].
In this retrospective review of a cohort of patients with high-
grade conventional osteosarcoma of the extremity, we investigate
the value of serum alkaline phosphatase (ALP) and lactate dehy-
drogenase (LDH) in predicting the presence of pulmonary and
skeletal metastates at time of diagnosis.2. Methods
A retrospective review was performed of the records of all
patients with osteosarcoma who were referred to our tertiary level
orthopaedic oncology unit, over the 5 year period from 2010 to
2014. Ethical approval was obtained from the relevant ethics re-
view board prior commencement of the study (UHERB Ref No. 02–
012013). All patients with histologically conﬁrmed high-grade
conventional osteosarcoma of an extremity were included in the
study. Exclusion criteria included involvement of the axial skele-
ton, soft tissue osteosarcoma, surface lesions and other osteo-
sarcoma subtypes.
2.1. Pre-treatment evaluation
Systemic staging involved standard laboratory investigations
(including serum ALP and LDH), CT-scan of the patient's chest and
abdomen, as well as a Technesium bonescan. The patient's charts
were subsequently reviewed and data extracted in order to de-
scribe the patient demographics, ALP and LDH levels, tumour vo-
lume, as well as the presence of pulmonary or skeletal metastases.
Pulmonary metastases was deﬁned as both parenchymal and
pleural metastatic lesions, while skeletal metastases included both
skip lesions and peripheral bony metastases. A bonescan was not
performed on four patients due the fact that their general condi-
tion did not permit transport to the centre where this was per-
formed. Serum LDH, reported in International Units per Liter (IU/L)
was determined using the Dimensions LDI method (Siemens,
Munich, Germany). Serum ALP (IU/L) was determined using Di-
mensions ALPI method (Siemens, Munich, Germany). Tumour
volume was calculated based on MRI (magnetic resonance ima-
ging) images using the formula for an ellipsoidal tumour mass,
where volume¼(π/6) lengthwidthheight, as previously de-
scribed [10,11]. Histology was obtained by formal incisional biopsy
in all cases and the diagnosis was subsequently conﬁrmed at a
combined radiology-histology meeting.
2.2. Statistical analysis
Data were processed and analysed using Stata 13.0 SE (Stata-
Corp, 2013. Stata Statistical Software: Release 13. College Station,
TX: StataCorp LP) and R statistical package 3.0.3 (R Core Team,
2015. R: A language and environment for statistical computing. R
Foundation for Statistical Computing, Vienna, Austria). Differences
in mean age, LDH and ALP by metastases were tested using the
standard two-sample t-test. Receiver operating characteristic
(ROC) curves were used to determine the optimal breakpoint for
the classiﬁcation of metastatic cancer based on LDH and/or ALPlevels. The criterion of the point on the ROC curve closest to the
point (0,1), i.e, upper left corner of the unit square, was used to
identify the optimal breakpoints [12,13]. The discriminatory power
was evaluated by the area under the ROC curve (AUC). An AUC
value of 0.5 indicates no discriminative ability while an AUC ex-
ceeding 0.8 suggest good to excellent predictive capability. Sensi-
tivity and speciﬁcity based on the optimal identiﬁed cut-points
were also calculated, along with 95% conﬁdence intervals. Logistic
regression analysis was then employed to estimate the strength of
association between categorical ALP and LDH versus metastases. A
p-value of o0.05 was considered statistically signiﬁcant for all
tests.3. Results
Sixty-seven patients were identiﬁed with histologically con-
ﬁrmed osteosarcoma involving an extremity. Six patients were
excluded from study. One patient passed away prior to completion
of systemic staging investigations and ﬁve patients were diag-
nosed with osteosarcoma variants. Sixty-one patients met the in-
clusion criteria and their clinical characteristics are listed in ta-
ble 1. The mean patient age was 21 years (standard deviation [SD]
11.9 years) and there was an equal distribution between male and
female patients (50.8 vs 49.2%). The incidence of pulmonary and
skeletal metastases did not vary signiﬁcantly according to the age
(p¼0.16 and p¼0.27, respectively). The majority of patients (98%)
where of African descent. The femur (57%) and tibia (31%) were
involved in the majority of cases.
Only 19.7% (n¼12) of patients had no evidence of metastatic
disease at time of presentation. Seventy-two percent (n¼44) had
pulmonary metastases. No other visceral metastases, including
liver metastases, were detected on the chest and abdominal CT-
scans. Twenty eight percent (n¼16) of patients who had a bone-
scan had evidence of skeletal metastases at the time of presenta-
tion. The incidence of pulmonary and skeletal metastases did not
vary signiﬁcantly according to patient age (p¼0.10 and p¼0.14,
respectively). The serum levels of LDH were not signiﬁcantly dif-
ferent in patients with or without pulmonary metastases (p¼0.88
and p¼0.47, respectively) (Table 2). The serum LDH and ALP levels
did however differ signiﬁcantly in patients with or without ske-
letal metastases (po0.001 and p¼0.02, for LDH and ALP,
respectively).
Optimal breakpoint analysis of serum LDH as a predictor of
pulmonary metastases revealed an area under the receiver op-
erator curve (AUC) of 0.569 (Fig. 1). The optimal breakpoint for
serum LDH as a marker of skeletal metastases was 849 IU/L (AUC
0.839; sensitivity¼0.88; speciﬁcity¼0.73) (Fig. 1). Serum LDH of
454 IU/L equated to 100% sensitivity for detected bone metastases
with a positive diagnostic likelihood ratio (DLR) of 1.32 (95% CI
1.1–1.6). The optimal breakpoint analysis of ALP and pulmonary
metastases revealed poor correlation (AUC 0.516). The optimal
breakpoint for serum ALP as a marker of skeletal metastases was
283 IU/L (AUC 0.771; sensitivity¼0.81; speciﬁcity¼0.76) (Fig. 2). A
serum ALP level of 76 IU/l was 100% sensitive in predicting the
presence of skeletal metastases (positive DLR 1.1; 95% CI 1.0–1.2).
Logistic regression analysis conﬁrmed that serum LDH and ALP
were signiﬁcant prognostic factors for skeletal metastases at time
of presentation. Univariate analysis of serum LDH 4850 IU/L re-
vealed an odds ratio (OR) of 10.9 (95% CI 2.6–46.1) for the presence
of skeletal metastases (po0.01) and for serum ALP 4280 IU/L the
OR was 12.4 (95% CI 2.9–53.0). In a multivariate analysis of serum
ALP and LDH both factors remained predictive of skeletal metas-
tases. However, with the addition of pre-treatment tumour vo-
lume LDH lost its signiﬁcance (Table 3).
Table 1
Clinical characteristics and descriptive statistics of cohort.
n Percentage Mean Range SD
Age 61 21.3 years 6–56 years 11.9 years
Sex
Male 31 50.8% – – –
Female 30 49.2% – – –
Site
Femur 35 57.4% – – –
Tibia 19 31.2% – – –
Humerus 3 4.9% – – –
Fibula 3 4.9% – – –
Ulna 1 1.6% – – –
Pulmonary
metastasis
Yes 44 72.1% – – –
No 17 27.9% – – –
Skeletal
metastasis
Yes 16 26.2% – – –
No 41 67.2% – – –
Unknown 4 6.6% – – –
LDH 61 1156.9 IU/L 269–6135 IU/L 1030.0 IU/L
ALP 61 570.3 IU/L 49–9594 IU/L 1293.4 IU/L
Tumour volume 51 1114.3 cm3 164–6821 cm3 1285.8 cm3
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The presence of metastases at the time of diagnosis is a sig-
niﬁcant prognostic factor in osteosarcoma [14]. Skeletal metas-
tases at time of presentations appears to carry a worse prognosis
than pulmonary metastases [15]. Furthermore, the chance of sur-
vival can be improved by surgical resection of all metastases [16].
Systemic staging and the search for the presence of metastases
therefore form an integral part of the initial diagnostic work-up of
a patient with osteosarcoma. The aim of this study was to de-
termine the value of pre-treatment serum LDH and ALP in pre-
dicting the presence of skeletal or pulmonary metastases in pa-
tients with conventional high-grade osteosarcoma of the ex-
tremities. Neither serum ALP or LDH was found to be of value as
prognostic factors for the presence of pulmonary metastases. In
terms of skeletal metastases both serum ALP and LDH were found
to be signiﬁcant. Serum LDH, however, lost its statistical sig-
niﬁcance in a multivariate model that included tumour volume.Table 2
Two-sample t-test of serum LDH and ALP as a predictors of the presence of metastasis
Positive
n (%) 95% CI
LDH
Pulmonary metastasis 44 (72.1%) 573.7–1676.7
Skeletal metastasis 16 (28.1%) 1163.5–2785.8
ALP
Pulmonary metastasis 44(72.1%) 189.3–1101.2
Skeletal metastasis 16 (28.1%) 59.8–2398.3Lactate dehydrogenase is known to reﬂect systemic cancer
burden and its prognostic signiﬁcance has been illustrated in
various malignancies, including Ewing's sarcoma [17,18].
A recent meta-analysis of studies evaluating the effect of high
LDH levels on overall survival found a pooled hazard ratio of 1.92
(95% CI 1.53–2.40) [19]. The Multi-Institutional Osteosarcoma
Study (MIOS) found serum LDH to be the single most predictive
factor of adverse outcome [20]. At 6 year follow-up of patients
diagnosed with osteosarcoma of the extremities, the event-free
survival was 41% for patients with elevated LDH levels compared
to 69% for the patients who had normal LDH at diagnosis
(po0.001). A study looking speciﬁcally at the prognostic value of
LDH in patient with osteosarcoma of the extremities, found that
patients who presented without metastases and an increased
serum LDH level were also far more likely to develop relapse of
disease than those with normal LDH values (60% vs 38%, po0.001)
[21].
Plasma bone-speciﬁc ALP has been suggested as a reliable tu-
mour marker for osteosarcoma [22]. Multivariate analysis per-
formed by Mialou et al. identiﬁed serum ALP levels in excess of
500 IU/L as an independent risk factor for decreased disease-free
and overall survival rates [23]. Furthermore, a reduction in ALP
levels following chemotherapy has been shown to correlate with
improved response to chemotherapy and survival [24]. On the
other hand, some authors have found that serum ALP did not have
prognostic value in terms of disease outcome [4].
Although pre-treatment LDH and ALP levels have been shown
to serve as a reliable indicator of disease-free survival, its value in
predicting the presence of metastases at time of diagnosis remains
unclear. In their initial series, Bacci et al. found that the percentage
of patients with an elevated serum LDH at the time of diagnosis
was signiﬁcantly higher in patients with metastatic disease than
those who had localised disease (64% versus 33%, po0.0001) [18].
In a larger follow-up series from the Rizzoli institute, involving
1421 patients seen over a 30 year period, it was noted that 18% of
patients with localized disease had elevated LDH levels at pre-
sentation compared to 36% of patients with metastatic disease
(po0.0001) [25]. Although high LDH levels were able to predict
the presence of metastases with a high degree of speciﬁcity (0.81),
sensitivity was found to be low (0.38). There was however no
differentiation made between skeletal and pulmonary metastases
in these studies. To the best of our knowledge this is the ﬁrst re-
port looking speciﬁcally at the predictive value of ALP and LDH in
detecting skeletal metastases. In our series serum LDH appeared to
be predictive for skeletal, but not pulmonary metastases. Serum
LDH, with a cut-off value of 849 IU/L, had a sensitivity of 0.88 and
speciﬁcity of 0.73 as a marker of skeletal metastases.
Multivariate logistic regression analysis by Bacci et al. found
that only tumour site (femur and humerus), increased alkaline
phosphatase (ALP), tumour volume (4150 ml) and duration of
symptoms (less than 2 months) were signiﬁcant factors in the
prediction of the presence of metastases at time of presentationat time of diagnosis.
Negative p-Value
n (%) 95% CI
17 (27.9%) 857.4–1480.9 0.88
41 (51.9%) 631.5–892.6 o0.001
17 (27.9%) 162.2–590.8 0.43
41 (51.9%) 164.3–471.6 0.02
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Fig. 1. Receiver operator curve of optimal breakpoint serum LDH as a predictor of metastasis at time of diagnosis. (a) Pulmonary metastases (b) Skeletal metastases.
Table 3
Multivariate analysis of ALP, LDH and tumour volume as a predictors of the pre-
sence of skeletal metastasis at time of presentation.
Measure OR p-Value 95% CI
LDH Z850 IU/L 2.8 0.97 0.4–20.0
ALP Z280 IU/L 9.8 0.02 1.3–70.9
Tumour volume Z1380 cm3 8.7 0.03 1.1–67.2
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tastases in patients with a pre-treatment serum ALP increased
more than twice the upper limit of normal (34% vs 12%; p¼0.007)
[27]. Similarly, the Rizolli group found increased ALP levels in
patients with metastases at time of diagnosis (91.5% vs 61.3%;
po0.001) [28]. The authors did not distinguish skeletal from
pulmonary metastases at time of presentation in relation the ALP.
Furthermore, there was an increased relapse rate in patients who
presented with localized disease and increased ALP levels (55.1%
vs 26.4%; po0.001). The authors noted however that there was no
difference in the site of ﬁrst metastases related to value of the ALP
level. Our ﬁndings suggest that normal serum ALP levels may be
predictive of the absence of skeletal metastases at the time of
diagnosis. With a cut-off of 76 IU/L a sensitivity of 100% was
reached. Serum ALP remained a signiﬁcant predictor in a multi-
variate model that included the pre-treatment tumour volume,
with an odds ratio of 9.8 (p¼0.02) for skeletal metastases if pre-
treatment ALP Z280 IU/L.
There are several shortcomings to this study that need to be
considered. The small size of this series is an obvious shortcoming.
Due to the relative rarity of the disease, this problem is not unique
to this series and authors of a recent meta-analysis noted the small
sample size of other studies as an obstacle in drawing ﬁrm con-
clusions regarding prognostic implications of LDH in terms of
survival. The small number of patients without metastases in this0.0 0.2 0.4 0.6 0.8 1.0
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Fig. 2. Receiver operator curve of optimal breakpoint serum ALP as a predictor of mseries would adversely affect the ROC analysis and therefore the
suggested cut-off values. Numerous patients were lost to follow-
up in our series and the long-term survival could not be de-
termined. The cohort of patients in our series is also not directly
comparable to those in other studies. The incidence of metastases
(80%) at time of diagnosis were much higher than the 14% re-
ported by Bacci et al. Furthermore, the mean tumour volume in
this series was much higher than in previous reports [29]. These
factors suggest that the cancer was either more advanced, both
locally and systemically, or more aggressive in nature in our series
of cases. The higher incidence of metastases in this series did
however enable us to determine more sensitive cut-off points for
the proposed prognostic indicators. Our results suggest that the
sensitivity of ALP and LDH in predicting the presence of skeletal
metastases may be improved by using a cut-off point of 75 IU/L0.0 0.2 0.4 0.6 0.8 1.0
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etastasis at time of diagnosis. (a) Pulmonary metastases (b) Skeletal metastases.
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The ﬁndings of this study should be borne in mind during the
initial staging and follow-up of a patient presenting with osteo-
sarcoma. 18F-ﬂuorodeoxy-D-glucose (FDG) positron emission to-
mography (PET) has been found to be more sensitive in the de-
tection of skeletal metastases from sarcomas [30]. The sensitivity
and speciﬁcity of spiral CT (computed tomography) however re-
mains superior to FDG-PET in the detection of lung metastases
[31]. In cases of osteosarcoma with LDH 4850IU/L and/or ALP
4280IU/L at presentation it may thus be prudent to consider
spiral CT and FDG-PET in the initial systemic staging of the patient.
In addition, the follow-up of patients who present with a high ALP
and/or LDH should possibly also be more rigorous. ESMO currently
recommends the use of X-rays or CT scan in the follow-up of pa-
tients [32]. However, thought should be given to the use of spiral
chest CT and FDG-PET or technetium bone scintigraphy during the
follow-up patients with high LDH and ALP levels in order to detect
metastases early.5. Conclusion
In cases of osteosarcoma with LDH 4850 IU/L and/or ALP
4280 IU/L it may be prudent to consider more sensitive staging
investigations for detection of skeletal metastases. Further re-
search is required to determine the value and the most sensitive
cut-off points of serum ALP and LDH in the prediction of skeletal
metastases. This data may be of value in certain resource con-
strained clinical environments where special investigations like
bone scintigraphy or FDG-PET may not be widely available.Acknowledgements
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